- 3874 San Jose Park Drive Suite 5, Jacksonville, FL 32217 | Phone: 904-799-2531
Our approach to care begins with a comprehensive functional medicine evaluation and an individualized review of current research, biomarkers, and clinical context. We integrate evidence-based medical practice with emerging areas of scientific investigation—such as peptide research, including compounds like BPC-157—to better understand underlying physiological patterns rather than isolated symptoms. This integrative model emphasizes patient education, informed decision-making, and personalized care planning while maintaining appropriate regulatory and clinical standards. functional medicine and peptide therapy services when clinically appropriate to support overall metabolic, hormonal, and long-term health.
✔ Medically Supervised
✔ Individualized Dosing
✔ Lab-guided Monitoring
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide based on a sequence originally identified in human gastric juice. It is primarily studied in laboratory and animal research settings for its biological signaling properties.
BPC-157 consists of a specific 15–amino acid sequence and is classified as a gastric pentadecapeptide. Its structure and molecular characteristics have been well defined in preclinical research.
Research on BPC-157 has focused on cytoprotective, gastrointestinal, and tissue-response mechanisms observed in animal and in-vitro models. BPC-157 is not FDA-approved, and findings from preclinical studies do not establish clinical efficacy in humans.
Laboratory and animal studies have explored BPC-157 across multiple biological systems, focusing on its potential interactions with cellular protective mechanisms, inflammatory signaling, and tissue-level responses to injury. These observations are derived exclusively from preclinical research and do not establish clinical efficacy or therapeutic benefit in humans.
Preclinical findings suggest that BPC-157 may influence microscopic tissue processes, including fibroblast migration, collagen organization, and adaptive modulation of angiogenesis. Experimental models have examined tissue response in tendon, ligament, muscle, bone, and skin following injury. Gastrointestinal research has further evaluated BPC-157 in models of gastric mucosal protection, stress- and NSAID-associated injury, inflammatory bowel disease, and maintenance of epithelial barrier integrity. All such findings remain investigational and cannot be extrapolated to clinical treatment recommendations.
Additional laboratory studies have investigated BPC-157’s interactions with inflammatory and oxidative stress pathways, including nitric oxide–dependent signaling, cytokine modulation, and angiogenic mediators such as VEGF, FGF, and TGF-β. Intracellular signaling proteins, including paxillin and focal adhesion kinase (FAK), have also been evaluated in experimental settings, offering possible explanations for observed cellular resilience in non-human models.
Preclinical research has also examined neurological and cardiovascular signaling pathways, including serotonergic, dopaminergic, GABAergic, and opioid systems, as well as nitric oxide–mediated vascular regulation. Animal models have explored potential effects in nerve injury, neuroinflammation, alcohol exposure, and cardiac rhythm disturbances; however, these findings remain preliminary and have not been validated in human clinical trials.
Finally, experimental literature characterizes BPC-157 as angiomodulatory, with reported context-dependent effects on angiogenesis. Laboratory studies have examined VEGF signaling regulation, inhibition of growth in select tumor cell lines, and experimental use in cancer cachexia models. Because angiogenesis plays a critical role in malignancy, any investigational compound influencing vascular signaling warrants caution. BPC-157 has no FDA-approved oncologic indication.
Animal and observational reports describe BPC-157 as having a favorable safety profile in experimental settings, though:
Human safety data are limited
Pediatric safety has not been established
Rare adverse effects have been reported in non-clinical contexts
No conclusions regarding safety or tolerability in humans should be drawn outside of controlled clinical trials.
If you are considering peptide therapy, the first step is a comprehensive medical evaluation to review your symptoms, health history, and clinical context.
Individualized care • Medically supervised • Lab-guided treatment
At Intercoastal Health, our peptide clinic in Jacksonville, Florida provides an evidence-informed, patient-centered approach to integrative care. Serving individuals throughout Jacksonville and Northeast Florida, we emphasize comprehensive functional medicine evaluations, detailed biomarker review, and education on emerging areas of research—including peptide science—within appropriate clinical and regulatory standards. Our focus is on individualized assessment and thoughtful care planning rather than one-size-fits-all solutions.
All discussions related to peptide therapy at Intercoastal Health are conducted under medical oversight with an emphasis on transparency, patient education, and safety. Investigational peptides are reviewed responsibly, with clear communication regarding FDA status, current research limitations, and clinical considerations. Through this integrative framework, we support informed decision-making and personalized care for patients seeking advanced medical evaluation in the Jacksonville, FL area.
We provide services in hormone replacement therapy in additional to peptide therapy jacksonville, longevity medicine services, or our car accident medical care.
Business Hours
Monday: 9AM – 6PM
Tuesday: 9AM – 6PM
Wednesday: 9AM – 6PM
Thursday: 9AM – 6PM
Friday: 9AM – 6PM
Saturday: Closed
Sunday: Closed
Comprehensive care with a whole person approach, specializing in injury management, wellness, and longevity.
3874 San Jose Park Drive
Suite 5
Jacksonville, Florida 32217
Intercoastal Health – Copyright © 2026 All Rights Reserved - Privacy Policy